FDA to Use GVKBio’s Biomarker DB in Voluntary Exploratory Data Program | GenomeWeb
NEW YORK (GenomeWeb News) - GVK Biosciences today said it has inked an agreement that will give the US Food and Drug Administration access to the company’s Clinical Biomarker Database.
 
Under the agreement, the FDA will use the database as part of its Voluntary Exploratory Data Submission Program and in internal research projects.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.